Cancer
Posted on: Aug 16 Hosted By: Barbara Lewis
Cancer
Posted on: Aug 16 Hosted By: Barbara Lewis
Views6488 Shares0
Tags: cancer, skin, melanoma, clinical trials, podcast

Promising Metastatic Melanoma Therapies

Guest: Doug Schwartzentruber, MD

Metastatic melanoma—the kind of cancer that spreads beyond the original site on the skin—is a difficult cancer to treat with very few effective options for patients. The FDA has approved two drugs for the treatment: (1) vemurafenib and (2) ipilimumab. In this podcast Doug Schwartzentruber, MD, who’s been working on a preventive vaccine for melanoma, discusses these two treatments. He shares with us the mechanism of action for vemurafenib (it inhibits BRAF kinase) and discusses its tolerability and clinical response rates.

With these new drugs comes a need to find a place for them within the treatment algorithm, along with vaccines, chemotherapy, and other treatments with differing molecular targets. He provides information on another molecular target—CTLA-4, or ipilimumab— which demonstrated a survival advantage the findings of which were presented at the American Society of Clinical Oncology.
 

Tags: cancer, skin, melanoma, clinical trials, podcast
What do you think of this podcast?

Promising Metastatic Melanoma Therapies

Guest: Doug Schwartzentruber, MD

Metastatic melanoma—the kind of cancer that spreads beyond the original site on the skin—is a difficult cancer to treat with very few effective options for patients. The FDA has approved two drugs for the treatment: (1) vemurafenib and (2) ipilimumab. In this podcast Doug Schwartzentruber, MD, who’s been working on a preventive vaccine for melanoma, discusses these two treatments. He shares with us the mechanism of action for vemurafenib (it inhibits BRAF kinase) and discusses its tolerability and clinical response rates.

With these new drugs comes a need to find a place for them within the treatment algorithm, along with vaccines, chemotherapy, and other treatments with differing molecular targets. He provides information on another molecular target—CTLA-4, or ipilimumab— which demonstrated a survival advantage the findings of which were presented at the American Society of Clinical Oncology.
 

What do you think of this podcast? print